Three treatments by Ipsen, Eisai and Bayer for thyroid cancer all recommended for NHS use by NICE

NICE has recommend that three separate treatments for thyroid cancer should be made available for use on the NHS: Ipsen’s Cometriq, Bayer’s Nexavar, and Eisai’s Lenvima. The former two were previously only available via the Cancer Drugs Fund (CDF), and Eisai’s finally gains approval after delays of over two years. Eisai’s tyrosine kinase inhibitor was

Continue Reading

Eisai Submits Lenvatinib for US and European Regulatory Approval

Eisai have confirmed that they have submitted their anticancer agent, Lenvatinib, with regulatory agencies in both Europe and the US. Specifically, Lenvatinib has been submitted for progressive radioiodine-refractory, differentiated thyroid cancer. The regulatory submissions are based on a 392-patient Phase III clinical trial, which showed the drug achieved a statistically significant improvement in progression-free survival.

Continue Reading

Eisai Suspends Epilepsy Drug, Fycompa, in Germany

Eisai is to suspend commercial distribution of its new epilepsy drug Fycompa in Germany, noting that they continue to disagree with the country’s reimbursement regulatory body’s rejection of the therapy. In March, the German Federal Joint Committee declared that they consider the additional benefit of Fycompa unproven when compared to two other treatments – GlaxoSmithKline’s

Continue Reading

Arena and Eisai Resubmit Lorcaserin to FDA

Arena Pharmaceuticals and partner Eisai are optimistic that regulators will approve their obesity drug, lorcaserin, after responding to a rejection issued by the US Food and Drug Administration in October 2010. Arena has submitted their response to the comprehensive reply letter from the Food and Drug Administration which cited a number of reasons for their

Continue Reading

Eisai’s Halaven Receives Final Draft “No” From NICE

In final draft guidance given yesterday, the National Institute for Health and Clinical Excellence (NICE) announced that they are not recommending Eisai’s Halaven (eribulin) for the treatment of locally-advanced or metastatic breast cancer in people whose disease has progressed after at least two chemotherapeutic regimens for advanced disease. Although the evidence shown to NICE’s independent

Continue Reading